Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Malignant Lymphoma

  Free Subscription


Articles published in Br J Haematol

Retrieve available abstracts of 231 articles:
HTML format
Text format



Single Articles


    December 2017
  1. SCHICK M, Habringer S, Nilsson JA, Keller U, et al
    Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers.
    Br J Haematol. 2017;179:724-738.
    PubMed     Text format     Abstract available


    November 2017
  2. FLINN IW, Thompson DS, Boccia RV, Miletello G, et al
    Bendamustine, bortezomib and rituximab produces durable complete remissions in patients with previously untreated, low grade lymphoma.
    Br J Haematol. 2017 Nov 28. doi: 10.1111/bjh.15044.
    PubMed     Text format     Abstract available


  3. ARCAINI L, Lamy T, Walewski J, Belada D, et al
    Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma.
    Br J Haematol. 2017 Nov 28. doi: 10.1111/bjh.15025.
    PubMed     Text format     Abstract available


  4. HOHLOCH K, Altmann B, Pfreundschuh M, Loeffler M, et al
    Obesity negatively impacts outcome in elderly female patients with aggressive B-cell lymphomas treated with R-CHOP: results from prospective trials of the German high grade non-Hodgkin's lymphoma trial group.
    Br J Haematol. 2017 Nov 28. doi: 10.1111/bjh.15029.
    PubMed     Text format     Abstract available


  5. ZAMO A, Pischimarov J, Horn H, Ott G, et al
    The exomic landscape of t(14;18)-negative diffuse follicular lymphoma with 1p36 deletion.
    Br J Haematol. 2017 Nov 28. doi: 10.1111/bjh.15041.
    PubMed     Text format     Abstract available


  6. FRAME IJ, Coberly J, Fuda FS, Chen M, et al
    Erythrophagocytosis by T-cell lymphoma cells in a patient with hereditary spherocytosis post-splenectomy.
    Br J Haematol. 2017 Nov 16. doi: 10.1111/bjh.15028.
    PubMed     Text format    


  7. KARAKAWA A, Taoka K, Kaburaki T, Tanaka R, et al
    Clinical features and outcomes of secondary intraocular lymphoma.
    Br J Haematol. 2017 Nov 16. doi: 10.1111/bjh.15005.
    PubMed     Text format    


  8. LIN RJ, Ma H, Guo R, Troxel AB, et al
    Potentially inappropriate medication use in elderly non-Hodgkin lymphoma patients is associated with reduced survival and increased toxicities.
    Br J Haematol. 2017 Nov 16. doi: 10.1111/bjh.15027.
    PubMed     Text format     Abstract available


  9. PFREUNDSCHUH M, Murawski N, Zeynalova S, Ziepert M, et al
    Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.
    Br J Haematol. 2017;179:410-420.
    PubMed     Text format     Abstract available


    October 2017
  10. GIULINO-ROTH L, O'Donohue T, Chen Z, Bartlett NL, et al
    Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
    Br J Haematol. 2017 Oct 29. doi: 10.1111/bjh.14951.
    PubMed     Text format     Abstract available


  11. PRETTYJOHNS M, Hoskin P, McNamara C, Linch D, et al
    The cost-effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma.
    Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.14990.
    PubMed     Text format     Abstract available


  12. QIU Y, Li Z, Pouzoulet F, Vishnu P, et al
    Immune checkpoint inhibition by anti-PDCD1 (anti-PD1) monoclonal antibody has significant therapeutic activity against central nervous system lymphoma in an immunocompetent preclinical model.
    Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.15009.
    PubMed     Text format    


  13. CHASE ML, Armand P
    Minimal residual disease in non-Hodgkin lymphoma - current applications and future directions.
    Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.14996.
    PubMed     Text format     Abstract available


  14. MANSO R, Sanchez-Beato M, Gonzalez-Rincon J, Gomez S, et al
    Mutations in the JAK/STAT pathway genes and activation of the pathway, a relevant finding in nodal Peripheral T-cell lymphoma.
    Br J Haematol. 2017 Oct 26. doi: 10.1111/bjh.14984.
    PubMed     Text format    


  15. GAUDIO E, Paduano F, Pinton S, D'Agostino S, et al
    TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line.
    Br J Haematol. 2017 Oct 19. doi: 10.1111/bjh.14989.
    PubMed     Text format    


  16. CORNISH N, Maybury B, Otton S
    A four-year spontaneous remission of angioimmunoblastic T-cell lymphoma.
    Br J Haematol. 2017 Oct 19. doi: 10.1111/bjh.14959.
    PubMed     Text format    


  17. EDLINGER L, Berger-Becvar A, Menzl I, Hoermann G, et al
    Expansion of BCR/ABL1+ cells requires PAK2 but not PAK1.
    Br J Haematol. 2017;179:229-241.
    PubMed     Text format     Abstract available


    September 2017
  18. THANARAJASINGAM G, Maurer MJ, Farooq U, Johnston PB, et al
    Event-free survival at 24 months captures central nervous system relapse of systemic diffuse large B-cell lymphoma in the immunochemotherapy era.
    Br J Haematol. 2017 Sep 29. doi: 10.1111/bjh.14922.
    PubMed     Text format    


  19. ADAMS HJA, Kwee TC
    Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma.
    Br J Haematol. 2017 Sep 14. doi: 10.1111/bjh.14906.
    PubMed     Text format    


  20. YAMANI F, Chen W
    Cytokeratin-positive primary effusion lymphoma: a diagnostic challenge.
    Br J Haematol. 2017 Sep 7. doi: 10.1111/bjh.14904.
    PubMed     Text format    


  21. PROCHAZKA KT, Posch F, Deutsch A, Beham-Schmid C, et al
    Immunohistochemical double hit score enhances NCCN-IPI and is associated with detrimental outcomes in refractory or relapsing patients with diffuse large B cell lymphoma.
    Br J Haematol. 2017 Sep 6. doi: 10.1111/bjh.14912.
    PubMed     Text format    


  22. OTT G
    Aggressive B-cell lymphomas in the update of the 4th edition of the World Health Organization classification of haematopoietic and lymphatic tissues: refinements of the classification, new entities and genetic findings.
    Br J Haematol. 2017;178:871-887.
    PubMed     Text format     Abstract available


  23. GOCKERITZ E, Vondey V, Guastafierro A, Pizevska M, et al
    Establishing a chemical genetic link between Bruton tyrosine kinase activity in malignant B cells and cell functions involved in the micro-environmental dialogue.
    Br J Haematol. 2017;178:949-953.
    PubMed     Text format     Abstract available


    August 2017
  24. EYRE TA, Phillips EH, Linton KM, Kassam S, et al
    Results of a multicentre UK-wide retrospective study evaluating the efficacy of brentuximab vedotin in relapsed, refractory classical Hodgkin lymphoma in the transplant naive setting.
    Br J Haematol. 2017 Aug 31. doi: 10.1111/bjh.14898.
    PubMed     Text format     Abstract available


  25. MUSSOLIN L, Pillon M, Zimmermann M, Carraro E, et al
    Course of anti-ALK antibody titres during chemotherapy in children with anaplastic large cell lymphoma.
    Br J Haematol. 2017 Aug 31. doi: 10.1111/bjh.14864.
    PubMed     Text format    


  26. DANN EJ, Paltiel O
    Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma: response to Adams and Kwee.
    Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14905.
    PubMed     Text format    


  27. RULE S, Dreyling M, Goy A, Hess G, et al
    Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies.
    Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14870.
    PubMed     Text format     Abstract available


  28. MILGROM SA, Pinnix CC, Chuang H, Oki Y, et al
    Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?
    Br J Haematol. 2017 Aug 18. doi: 10.1111/bjh.14902.
    PubMed     Text format     Abstract available


  29. COX MC, Di Napoli A, Fabbri A, Cencini E, et al
    The significance of serum immunoglobulin paraprotein in diffuse large B-cell lymphoma.
    Br J Haematol. 2017 Aug 17. doi: 10.1111/bjh.14873.
    PubMed     Text format    


  30. ALONSO-ALVAREZ S, Magnano L, Alcoceba M, Andrade-Campos M, et al
    Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group.
    Br J Haematol. 2017 Aug 7. doi: 10.1111/bjh.14831.
    PubMed     Text format     Abstract available


  31. KANATE AS, DiGilio A, Ahn KW, Al Malki M, et al
    Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14879.
    PubMed     Text format    


  32. JAIN P, Kanagal-Shamanna R, San Lucas FA, Nastoupil L, et al
    Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14857.
    PubMed     Text format    


  33. HAGNER PR, Chiu H, Ortiz M, Apollonio B, et al
    Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14866.
    PubMed     Text format     Abstract available


  34. FERRERI AJM, Cecchetti C, Kiesewetter B, Sassone M, et al
    Clarithromycin as a "repurposing drug" against MALT lymphoma.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14878.
    PubMed     Text format    


  35. ZWAAN CM, Kowalczyk J, Schmitt C, Bielorai B, et al
    Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14874.
    PubMed     Text format     Abstract available


  36. MAKAROVA O, Oschlies I, Muller S, Ruf S, et al
    Excellent outcome with limited treatment in paediatric patients with marginal zone lymphoma.
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14868.
    PubMed     Text format    


  37. DUROT E, Tomowiak C, Michallet AS, Dupuis J, et al
    Transformed Waldenstrom macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization (FILO).
    Br J Haematol. 2017 Aug 2. doi: 10.1111/bjh.14881.
    PubMed     Text format     Abstract available


  38. SROUR SA, Li S, Popat UR, Qazilbash MH, et al
    A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results.
    Br J Haematol. 2017;178:561-570.
    PubMed     Text format     Abstract available


  39. EYRE TA, Schuh A
    An update for Richter syndrome - new directions and developments.
    Br J Haematol. 2017;178:508-520.
    PubMed     Text format     Abstract available


    July 2017
  40. SHIVAROV V, Ivanova M
    Nodular lymphocyte predominant Hodgkin lymphoma in USA between 2000 and 2014: an updated analysis based on the SEER data.
    Br J Haematol. 2017 Jul 24. doi: 10.1111/bjh.14861.
    PubMed     Text format    


  41. CASCIONE L, Rinaldi A, Chiappella A, Kwee I, et al
    Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study.
    Br J Haematol. 2017 Jul 24. doi: 10.1111/bjh.14817.
    PubMed     Text format    


  42. DELLA PEPA R, Picardi M, Giordano C, Zacheo I, et al
    Rituximab in a risk-adapted treatment strategy gives excellent therapeutic results in nodular lymphocyte-predominant Hodgkin lymphoma.
    Br J Haematol. 2017 Jul 24. doi: 10.1111/bjh.14856.
    PubMed     Text format    


  43. WESTMORELAND KD, El-Mallawany NK, Kazembe P, Stanley CC, et al
    Dissecting heterogeneous outcomes for paediatric Burkitt lymphoma in Malawi after anthracycline-based treatment.
    Br J Haematol. 2017 Jul 17. doi: 10.1111/bjh.14716.
    PubMed     Text format    


  44. MANSO R, Martinez-Magunacelaya N, Chamizo C, Rojo F, et al
    Mutual regulation between BCL6 and a specific set of miRNAs controls TFH phenotype in peripheral T-cell lymphoma.
    Br J Haematol. 2017 Jul 12. doi: 10.1111/bjh.14824.
    PubMed     Text format    


  45. KABURAKI T, Taoka K, Matsuda J, Yamashita H, et al
    Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma.
    Br J Haematol. 2017 Jul 12. doi: 10.1111/bjh.14848.
    PubMed     Text format     Abstract available


  46. TOMITA N
    Histological assessment at follicular lymphoma progression.
    Br J Haematol. 2017 Jul 7. doi: 10.1111/bjh.14834.
    PubMed     Text format    


  47. DANG NH, Ogura M, Castaigne S, Fayad LE, et al
    Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
    Br J Haematol. 2017 Jul 5. doi: 10.1111/bjh.14820.
    PubMed     Text format    


  48. RUTHERFORD SC, Li V, Ghione P, Chen Z, et al
    Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trials.
    Br J Haematol. 2017 Jul 5. doi: 10.1111/bjh.14839.
    PubMed     Text format     Abstract available


  49. MENTER T, Juskevicius D, Alikian M, Steiger J, et al
    Mutational landscape of B-cell post-transplant lymphoproliferative disorders.
    Br J Haematol. 2017;178:48-56.
    PubMed     Text format     Abstract available


    June 2017
  50. FAROOQ U, Maurer MJ, Thompson CA, Thanarajasingam G, et al
    Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.
    Br J Haematol. 2017 Jun 27. doi: 10.1111/bjh.14813.
    PubMed     Text format     Abstract available


  51. BERNASCONI E, Gaudio E, Lejeune P, Tarantelli C, et al
    Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma.
    Br J Haematol. 2017 Jun 27. doi: 10.1111/bjh.14803.
    PubMed     Text format     Abstract available


  52. MODVIG L, Vase M, d'Amore F
    Clinical and treatment-related features determining the risk of late relapse in patients with diffuse large B-cell lymphoma.
    Br J Haematol. 2017 Jun 27. doi: 10.1111/bjh.14822.
    PubMed     Text format     Abstract available


  53. SZCZEPANOWSKI M, Lange J, Kohler CW, Masque-Soler N, et al
    Cell-of-origin classification by gene expression and MYC-rearrangements in diffuse large B-cell lymphoma of children and adolescents.
    Br J Haematol. 2017 Jun 23. doi: 10.1111/bjh.14812.
    PubMed     Text format     Abstract available


  54. PRATT G, Yap C, Oldreive C, Slade D, et al
    A multi-centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T-prolymphocytic leukaemia or mantle cell lymphoma.
    Br J Haematol. 2017 Jun 23. doi: 10.1111/bjh.14793.
    PubMed     Text format    


  55. STRUSSMANN T, Fritsch K, Baumgarten A, Fietz T, et al
    Favourable outcomes of poor prognosis diffuse large B-cell lymphoma patients treated with dose-dense Rituximab, high-dose Methotrexate and six cycles of CHOP-14 compared to first-line autologous transplantation.
    Br J Haematol. 2017 Jun 23. doi: 10.1111/bjh.14802.
    PubMed     Text format     Abstract available


  56. LI L, Duan W, Zhang L, Li X, et al
    The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.
    Br J Haematol. 2017 Jun 9. doi: 10.1111/bjh.14763.
    PubMed     Text format     Abstract available


  57. DANN EJ, Bairey O, Bar-Shalom R, Mashiach T, et al
    Modification of initial therapy in early and advanced Hodgkin lymphoma, based on interim PET/CT is beneficial: a prospective multicentre trial of 355 patients.
    Br J Haematol. 2017 Jun 7. doi: 10.1111/bjh.14734.
    PubMed     Text format     Abstract available


    May 2017
  58. TAO L, Clarke CA, Rosenberg AS, Advani RH, et al
    Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
    Br J Haematol. 2017 May 25. doi: 10.1111/bjh.14638.
    PubMed     Text format     Abstract available


  59. BECH RS, Nielsen KL, Larsen TS, Bentzen HH, et al
    Real world data on rituximab maintenance therapy after frontline immunochemotherapy in grade 1-3a follicular lymphoma.
    Br J Haematol. 2017 May 23. doi: 10.1111/bjh.14775.
    PubMed     Text format    


  60. FONSECA E SILVA D, Lopes MS, Pedrosa C, Regadas L, et al
    Burkitt lymphoma.
    Br J Haematol. 2017 May 16. doi: 10.1111/bjh.14758.
    PubMed     Text format    


  61. SHIMONO J, Miyoshi H, Kiyasu J, Sato K, et al
    Clinicopathological analysis of primary splenic diffuse large B-cell lymphoma.
    Br J Haematol. 2017 May 11. doi: 10.1111/bjh.14736.
    PubMed     Text format     Abstract available


  62. LI Y, Wang L, Zhu HY, Liang JH, et al
    Prognostic significance of serum immunoglobulin paraprotein in patients with diffuse large B cell lymphoma.
    Br J Haematol. 2017 May 11. doi: 10.1111/bjh.14735.
    PubMed     Text format    


  63. CHASTY B, Patterson M, Murray LJ, Johnson R, et al
    Lack of effectiveness of routine clinic and blood test-based follow-up for diffuse large B cell lymphoma.
    Br J Haematol. 2017 May 9. doi: 10.1111/bjh.14745.
    PubMed     Text format    


  64. CERIANI L, Martelli M, Conconi A, Zinzani PL, et al
    Prognostic models for primary mediastinal (thymic) B-cell lymphoma derived from 18-FDG PET/CT quantitative parameters in the International Extranodal Lymphoma Study Group (IELSG) 26 study.
    Br J Haematol. 2017 May 9. doi: 10.1111/bjh.14728.
    PubMed     Text format     Abstract available


  65. CEDERLEUF H, Bjerregard Pedersen M, Jerkeman M, Relander T, et al
    The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study.
    Br J Haematol. 2017 May 8. doi: 10.1111/bjh.14740.
    PubMed     Text format     Abstract available


  66. LEE S, Day NS, Miles RR, Perkins SL, et al
    Comparative genomic expression signatures of signal transduction pathways and targets in paediatric Burkitt lymphoma: a Children's Oncology Group report.
    Br J Haematol. 2017 May 4. doi: 10.1111/bjh.14604.
    PubMed     Text format     Abstract available


  67. BOYLE T, Connors JM, Gascoyne RD, Berry BR, et al
    Physical activity, obesity and survival in diffuse large B-cell and follicular lymphoma cases.
    Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14702.
    PubMed     Text format     Abstract available


  68. EPPERLA N, Pham AQ, Burnette BL, Wiseman GA, et al
    Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.
    Br J Haematol. 2017 May 3. doi: 10.1111/bjh.14688.
    PubMed     Text format     Abstract available


    April 2017
  69. EPPERLA N, Hamadani M, Fenske TS, Costa LJ, et al
    Incidence and survival trends in mantle cell lymphoma.
    Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14699.
    PubMed     Text format    


  70. BATLEVI CL, Crump M, Andreadis C, Rizzieri D, et al
    A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
    Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14698.
    PubMed     Text format     Abstract available


  71. HUSSAIN S, Hallam S, Beltran L, Haroon A, et al
    Intravascular large B-cell lymphoma presenting as a pituitary mass with bilateral adrenal enlargement and haemophagocytic lymphohistiocytosis.
    Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14715.
    PubMed     Text format    


  72. HUDE I, Sasse S, Brockelmann PJ, von Tresckow B, et al
    Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.
    Br J Haematol. 2017 Apr 25. doi: 10.1111/bjh.14705.
    PubMed     Text format    


  73. CAVALLI M, De Novi LA, Della Starza I, Cappelli LV, et al
    Comparative analysis between RQ-PCR and digital droplet PCR of BCL2/IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma.
    Br J Haematol. 2017 Apr 17. doi: 10.1111/bjh.14616.
    PubMed     Text format     Abstract available


  74. MARTIN P, Chen Z, Cheson BD, Robinson KS, et al
    Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
    Br J Haematol. 2017 Apr 17. doi: 10.1111/bjh.14667.
    PubMed     Text format     Abstract available


  75. TOKUNAGA M, Yonekura K, Nakamura D, Haraguchi K, et al
    Clinical significance of cutaneous adverse reaction to mogamulizumab in relapsed or refractory adult T-cell leukaemia-lymphoma.
    Br J Haematol. 2017 Apr 3. doi: 10.1111/bjh.14634.
    PubMed     Text format    


  76. WANG Z, Cook JR
    PDCD1LG2 (PD-L2) RNA in situ hybridization is a sensitive, specific, and practical marker of primary mediastinal large B-cell lymphoma.
    Br J Haematol. 2017 Apr 3. doi: 10.1111/bjh.14670.
    PubMed     Text format    


  77. SZYCHOT E, Shankar A, Haider A, Ramsay A, et al
    Variant histology nodular lymphocyte predominant Hodgkin lymphoma - a route to transformation?
    Br J Haematol. 2017 Apr 3. doi: 10.1111/bjh.14607.
    PubMed     Text format    


  78. SROUR SA, Lee HJ, Nomie K, Ye H, et al
    Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma.
    Br J Haematol. 2017 Apr 2. doi: 10.1111/bjh.14669.
    PubMed     Text format    


    March 2017
  79. EYRE TA, Osborne WL, Gallop-Evans E, Ardeshna KM, et al
    Results of a multicentre UK-wide compassionate use programme evaluating the efficacy of idelalisib monotherapy in relapsed, refractory follicular lymphoma.
    Br J Haematol. 2017 Mar 24. doi: 10.1111/bjh.14665.
    PubMed     Text format    


  80. NASTOUPIL LJ, McLaughlin P, Feng L, Neelapu SS, et al
    High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.
    Br J Haematol. 2017 Mar 24. doi: 10.1111/bjh.14541.
    PubMed     Text format     Abstract available


  81. MARQUET J, Piris-Villaespesa M, Rodriguez E, Lopez S, et al
    Skin lesions and cytological features in HTLV-1 associated adult T-cell leukaemia/lymphoma.
    Br J Haematol. 2017 Mar 14. doi: 10.1111/bjh.14600.
    PubMed     Text format    


  82. HORING E, Montraveta A, Heine S, Kleih M, et al
    Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.
    Br J Haematol. 2017 Mar 14. doi: 10.1111/bjh.14571.
    PubMed     Text format     Abstract available


  83. LI Z, Lu L, Zhou Z, Xue W, et al
    Recurrent mutations in epigenetic modifiers and the PI3K/AKT/mTOR pathway in subcutaneous panniculitis-like T-cell lymphoma.
    Br J Haematol. 2017 Mar 14. doi: 10.1111/bjh.14611.
    PubMed     Text format    


  84. CHEN RW, Li H, Bernstein SH, Kahwash S, et al
    RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.
    Br J Haematol. 2017;176:759-769.
    PubMed     Text format     Abstract available


    February 2017
  85. MOLIN D, Linderoth J, Wahlin BE
    Nodular lymphocyte predominant Hodgkin lymphoma in Sweden between 2000 and 2014: an analysis of the Swedish Lymphoma Registry.
    Br J Haematol. 2017 Feb 24. doi: 10.1111/bjh.14567.
    PubMed     Text format     Abstract available


  86. SHANKAR AG, Roques G, Kirkwood AA, Lambilliotte A, et al
    Advanced stage nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents: clinical characteristics and treatment outcome - a report from the SFCE & CCLG groups.
    Br J Haematol. 2017 Feb 21. doi: 10.1111/bjh.14518.
    PubMed     Text format     Abstract available


  87. ALFRED A, Taylor PC, Dignan F, El-Ghariani K, et al
    The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society.
    Br J Haematol. 2017 Feb 21. doi: 10.1111/bjh.14537.
    PubMed     Text format     Abstract available


  88. SAWAS A, Farber CM, Schreeder MT, Khalil MY, et al
    A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab.
    Br J Haematol. 2017 Feb 21. doi: 10.1111/bjh.14534.
    PubMed     Text format     Abstract available


  89. KARMALI R, Nabhan C, Petrich AM, Raizer J, et al
    Impact of treatment variability on survival in immuno-competent and immuno-compromised patients with primary central nervous lymphoma.
    Br J Haematol. 2017 Feb 17. doi: 10.1111/bjh.14522.
    PubMed     Text format     Abstract available


  90. GIFFORD G, Gabrielli S, Gill A, Greenwood M, et al
    Lymphoma cell-of-origin assignment by gene expression profiling is clinically meaningful across broad laboratory contexts.
    Br J Haematol. 2017 Feb 15. doi: 10.1111/bjh.14556.
    PubMed     Text format    


  91. GAO R, Liang JH, Wang L, Zhu HY, et al
    Low T3 syndrome is a strong prognostic predictor in diffuse large B cell lymphoma.
    Br J Haematol. 2017 Feb 1. doi: 10.1111/bjh.14528.
    PubMed     Text format     Abstract available


    January 2017
  92. MOK Y, Goh GH, Wang S
    Unusual cohesive growth pattern of diffuse large B-cell lymphoma mimicking metastatic carcinoma.
    Br J Haematol. 2017 Jan 20. doi: 10.1111/bjh.14500.
    PubMed     Text format    


  93. BARAS N, Dahm S, Haberland J, Janz M, et al
    Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012).
    Br J Haematol. 2017 Jan 20. doi: 10.1111/bjh.14530.
    PubMed     Text format     Abstract available


  94. MESGUICH C, Cazeau AL, Bouabdallah K, Hindie E, et al
    Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.
    Br J Haematol. 2017 Jan 20. doi: 10.1111/bjh.14494.
    PubMed     Text format    


  95. MONTALBAN C, Diaz-Lopez A, Dlouhy I, Rovira J, et al
    Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of beta2 -microglobulin yields a more accurate GELTAMO-IPI.
    Br J Haematol. 2017 Jan 20. doi: 10.1111/bjh.14489.
    PubMed     Text format     Abstract available


  96. COWAN AJ, Stevenson PA, Gooley TA, Frayo SL, et al
    Results of a phase I-II study of fenretinide and rituximab for patients with indolent B-cell lymphoma and mantle cell lymphoma.
    Br J Haematol. 2017 Jan 5. doi: 10.1111/bjh.14451.
    PubMed     Text format     Abstract available


  97. RUBIO-GONZALEZ B, Zain J, Rosen ST, Querfeld C, et al
    Clinical manifestations and pathogenesis of cutaneous lymphomas: current status and future directions.
    Br J Haematol. 2017;176:16-36.
    PubMed     Text format     Abstract available


    December 2016
  98. ADAMS HJ, Kwee TC
    Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations?
    Br J Haematol. 2016 Dec 26. doi: 10.1111/bjh.14495.
    PubMed     Text format    


  99. KALAC M, Lue JK, Lichtenstein E, Turenne I, et al
    Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
    Br J Haematol. 2016 Dec 16. doi: 10.1111/bjh.14449.
    PubMed     Text format    


  100. CHIHARA D, Fanale MA, Miranda RN, Noorani M, et al
    The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.
    Br J Haematol. 2016 Dec 16. doi: 10.1111/bjh.14477.
    PubMed     Text format     Abstract available


  101. VARDHANA SA, Sauter CS, Matasar MJ, Zelenetz AD, et al
    Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era.
    Br J Haematol. 2016 Dec 16. doi: 10.1111/bjh.14453.
    PubMed     Text format     Abstract available


  102. ALLEN PB, Pavone ME, Smith KN, Kazer RR, et al
    The impact of fertility preservation on treatment delay and progression-free survival in women with lymphoma: a single-centre experience.
    Br J Haematol. 2016 Dec 16. doi: 10.1111/bjh.14466.
    PubMed     Text format    


  103. SCHMITZ N, de Leval L
    How I manage peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma: current practice and a glimpse into the future.
    Br J Haematol. 2016 Dec 16. doi: 10.1111/bjh.14473.
    PubMed     Text format     Abstract available


    November 2016
  104. LITTOOIJ AS, Kwee TC, Enriquez G, Verbeke JI, et al
    Whole-body MRI reveals high incidence of osteonecrosis in children treated for Hodgkin lymphoma.
    Br J Haematol. 2016 Nov 28. doi: 10.1111/bjh.14452.
    PubMed     Text format     Abstract available


  105. MOLYNEUX E, Schwalbe E, Chagaluka G, Banda K, et al
    The use of anthracyclines in the treatment of endemic Burkitt lymphoma.
    Br J Haematol. 2016 Nov 28. doi: 10.1111/bjh.14440.
    PubMed     Text format     Abstract available


  106. KWIECINSKA A, Tsesmetzis N, Ghaderi M, Kis L, et al
    CD274 (PD-L1)/PDCD1 (PD-1) expression in de novo and transformed diffuse large B-cell lymphoma.
    Br J Haematol. 2016 Nov 23. doi: 10.1111/bjh.14432.
    PubMed     Text format    


  107. NISHINO M, Ramaiya NH, Hatabu H, Hodi FS, et al
    PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy.
    Br J Haematol. 2016 Nov 11. doi: 10.1111/bjh.14441.
    PubMed     Text format    


  108. DI NAPOLI A, Jain P, Duranti E, Margolskee E, et al
    Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A.
    Br J Haematol. 2016 Nov 10. doi: 10.1111/bjh.14431.
    PubMed     Text format    


    October 2016
  109. MELEN CM, Enblad G, Sonnevi K, Junlen HR, et al
    Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study.
    Br J Haematol. 2016 Oct 28. doi: 10.1111/bjh.14399.
    PubMed     Text format     Abstract available


  110. BARI A, Marcheselli L, Marcheselli R, Pozzi S, et al
    Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients.
    Br J Haematol. 2016 Oct 26. doi: 10.1111/bjh.14406.
    PubMed     Text format    


  111. LIU L, Giusti F, Schaapveld M, Aleman B, et al
    Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up.
    Br J Haematol. 2016 Oct 21. doi: 10.1111/bjh.14379.
    PubMed     Text format     Abstract available


  112. NISHIWAKI U, Nakayama S, Yokote T, Hiraoka N, et al
    Classical Hodgkin lymphoma producing macrophage colony-stimulating factor with resultant monocytosis.
    Br J Haematol. 2016 Oct 21. doi: 10.1111/bjh.14416.
    PubMed     Text format    


  113. WEBSTER A, Crea P, Bamford MW, Hew R, et al
    Enteropathy-associated T-cell lymphoma presenting as cutaneous deposits.
    Br J Haematol. 2016 Oct 21. doi: 10.1111/bjh.14375.
    PubMed     Text format    


  114. HAPGOOD G, Pickles T, Sehn LH, Villa D, et al
    Outcome of primary cutaneous anaplastic large cell lymphoma: a 20-year British Columbia Cancer Agency experience.
    Br J Haematol. 2016 Oct 21. doi: 10.1111/bjh.14404.
    PubMed     Text format     Abstract available


  115. KRIDEL R, Telio D, Villa D, Sehn LH, et al
    Diffuse large B-cell lymphoma with testicular involvement: outcome and risk of CNS relapse in the rituximab era.
    Br J Haematol. 2016 Oct 14. doi: 10.1111/bjh.14392.
    PubMed     Text format     Abstract available


  116. HILLS RK
    Treatment intensification in diffuse large B-Cell lymphoma: lessons for clinical trial design.
    Br J Haematol. 2016 Oct 13. doi: 10.1111/bjh.14400.
    PubMed     Text format    


  117. HERRERA AF, Kim HT, Kong KA, Faham M, et al
    Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma.
    Br J Haematol. 2016 Oct 6. doi: 10.1111/bjh.14311.
    PubMed     Text format     Abstract available


    September 2016
  118. EL-GALALY TC, Cheah CY, Hutchings M, Mikhaeel NG, et al
    Uterine, but not ovarian, female reproductive organ involvement at presentation by diffuse large B-cell lymphoma is associated with poor outcomes and a high frequency of secondary CNS involvement.
    Br J Haematol. 2016 Sep 29. doi: 10.1111/bjh.14325.
    PubMed     Text format     Abstract available


  119. BIGENWALD C, Harel S, Chevignon F, Roos-Weil D, et al
    Are myelodysplastic syndromes and acute myeloid leukaemia occurring during the course of lymphoma always therapy related?
    Br J Haematol. 2016 Sep 23. doi: 10.1111/bjh.14323.
    PubMed     Text format    


  120. RAMSEY SD, Nademanee A, Masszi T, Holowiecki J, et al
    Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma.
    Br J Haematol. 2016 Sep 21. doi: 10.1111/bjh.14316.
    PubMed     Text format     Abstract available


  121. POIREL HA, Vikkula M
    Age-related heterogeneity of Burkitt lymphoma: response to Mbulaiteye and Anderson.
    Br J Haematol. 2016 Sep 9. doi: 10.1111/bjh.14309.
    PubMed     Text format    


  122. JORGE IF, de Santana LR, Silveira MA, Brunetta DM, et al
    Oro-nasal myiasis in a lymphoma patient.
    Br J Haematol. 2016 Sep 9. doi: 10.1111/bjh.14319.
    PubMed     Text format    


  123. PLATTEL WJ, Alsada ZN, van Imhoff GW, Diepstra A, et al
    Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC.
    Br J Haematol. 2016 Sep 9. doi: 10.1111/bjh.14317.
    PubMed     Text format     Abstract available


  124. GHESQUIERES H, Larrabee BR, Casasnovas O, Maurer MJ, et al
    A susceptibility locus for classical Hodgkin lymphoma at 8q24 near MYC/PVT1 predicts patient outcome in two independent cohorts.
    Br J Haematol. 2016 Sep 9. doi: 10.1111/bjh.14306.
    PubMed     Text format    


  125. BRAS AE, Beishuizen A, Langerak AW, Jongen-Lavrencic M, et al
    CD38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy.
    Br J Haematol. 2016 Sep 8. doi: 10.1111/bjh.14310.
    PubMed     Text format    


    August 2016
  126. SUNER L, Gabignon C, Delhommeau F
    Reed Sternberg cell/lymphocyte rosettes in a bone marrow aspirate leading to the diagnosis of Hodgkin lymphoma.
    Br J Haematol. 2016 Aug 24. doi: 10.1111/bjh.14301.
    PubMed     Text format    


  127. MESGUICH C, Cazeau AL, Bouabdallah K, Soubeyran P, et al
    Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.
    Br J Haematol. 2016 Aug 19. doi: 10.1111/bjh.14292.
    PubMed     Text format     Abstract available


  128. CHIHARA D, Fowler NH, Oki Y, Fanale MA, et al
    Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.
    Br J Haematol. 2016 Aug 9. doi: 10.1111/bjh.14267.
    PubMed     Text format    


  129. GLEESON M, Hawkes EA, Cunningham D, Chadwick N, et al
    Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trial.
    Br J Haematol. 2016 Aug 1. doi: 10.1111/bjh.14287.
    PubMed     Text format     Abstract available


    July 2016
  130. CHEAH CY, Joske D, Cull G, Gilbertson M, et al
    High-dose therapy and autologous stem cell transplantation may only be applicable to selected patients with secondary CNS diffuse large B-cell lymphoma.
    Br J Haematol. 2016 Jul 29. doi: 10.1111/bjh.14187.
    PubMed     Text format    


  131. MBULAITEYE SM, Anderson WF
    Age-related heterogeneity of Burkitt lymphoma.
    Br J Haematol. 2016 Jul 29. doi: 10.1111/bjh.14288.
    PubMed     Text format    


  132. LANDSBURG DJ, Falkiewicz MK, Petrich AM, Chu BA, et al
    Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable.
    Br J Haematol. 2016 Jul 29. doi: 10.1111/bjh.14282.
    PubMed     Text format     Abstract available


  133. MAESHIMA AM, Taniguchi H, Toyoda K, Yamauchi N, et al
    Clinicopathological features of histological transformation from extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue to diffuse large B-cell lymphoma: an analysis of 467 patients.
    Br J Haematol. 2016 Jul 27. doi: 10.1111/bjh.14153.
    PubMed     Text format     Abstract available


  134. CHEN Y, Neelapu S, Feng L, Bi W, et al
    Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum beta2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.
    Br J Haematol. 2016 Jul 22. doi: 10.1111/bjh.14237.
    PubMed     Text format     Abstract available


  135. PARK SI, Grover NS, Olajide O, Asch AS, et al
    A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphoma.
    Br J Haematol. 2016 Jul 22. doi: 10.1111/bjh.14232.
    PubMed     Text format     Abstract available


  136. HOWELL M, Gibb A, Radford J, Linton K, et al
    Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
    Br J Haematol. 2016 Jul 22. doi: 10.1111/bjh.14257.
    PubMed     Text format    


  137. KANSARA R, Villa D, Gerrie AS, Klasa R, et al
    Site of central nervous system (CNS) relapse in patients with diffuse large B-cell lymphoma (DLBCL) by the CNS-IPI risk model.
    Br J Haematol. 2016 Jul 22. doi: 10.1111/bjh.14229.
    PubMed     Text format    


  138. STARR AG, Caimi PF, Fu P, Massoud MR, et al
    Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.
    Br J Haematol. 2016 Jul 22. doi: 10.1111/bjh.14228.
    PubMed     Text format     Abstract available


  139. NGUYEN VT, Pophali PA, Tsai JP, Jagadeesh D, et al
    Early stage, bulky Hodgkin lymphoma patients have a favorable outcome when treated with or without consolidative radiotherapy: potential role of PET scan in treatment planning.
    Br J Haematol. 2016 Jul 13. doi: 10.1111/bjh.14236.
    PubMed     Text format    


  140. PILLON M, Mussolin L, Carraro E, Conter V, et al
    Detection of prognostic factors in children and adolescents with Burkitt and Diffuse Large B-Cell Lymphoma treated with the AIEOP LNH-97 protocol.
    Br J Haematol. 2016 Jul 8. doi: 10.1111/bjh.14240.
    PubMed     Text format     Abstract available


  141. UJJANI CS, Cheson BD
    Overestimated value of FDG-PET based bone marrow evaluation in lymphoma: Response to Adams and Kwee.
    Br J Haematol. 2016 Jul 8. doi: 10.1111/bjh.14216.
    PubMed     Text format    


  142. TIAN C, Wang X, Zhang Y
    Glomerular infiltration by intravascular large B-cell lymphoma.
    Br J Haematol. 2016 Jul 8. doi: 10.1111/bjh.14204.
    PubMed     Text format    


  143. SORIGUE M, Sancho JM, Ribera JM
    Open questions in watchful waiting for follicular lymphoma.
    Br J Haematol. 2016 Jul 8. doi: 10.1111/bjh.14246.
    PubMed     Text format    


  144. ESKELUND CW, Kolstad A, Jerkeman M, Raty R, et al
    15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.
    Br J Haematol. 2016 Jul 5. doi: 10.1111/bjh.14241.
    PubMed     Text format     Abstract available


  145. CHIHARA D, Westin JR, Miranda RN, Cheah CY, et al
    Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma.
    Br J Haematol. 2016 Jul 5. doi: 10.1111/bjh.14226.
    PubMed     Text format    


  146. SHAH GL, Yahalom J, Matasar MJ, Verwys SL, et al
    Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation.
    Br J Haematol. 2016 Jul 5. doi: 10.1111/bjh.14245.
    PubMed     Text format     Abstract available


    June 2016
  147. ADAMS HJ, Kwee TC
    Overestimated value of FDG-PET based bone marrow evaluation in lymphoma.
    Br J Haematol. 2016 Jun 28. doi: 10.1111/bjh.14217.
    PubMed     Text format    


  148. BLAKER YN, Spetalen S, Brodtkorb M, Lingjaerde OC, et al
    The tumour microenvironment influences survival and time to transformation in follicular lymphoma in the rituximab era.
    Br J Haematol. 2016 Jun 24. doi: 10.1111/bjh.14201.
    PubMed     Text format     Abstract available


  149. BONTKES HJ, Jordanova ES, Nijeboer P, Neefjes-Borst EA, et al
    High myeloid-derived suppressor cell frequencies in the duodenum are associated with enteropathy associated T-cell lymphoma and its precursor lesions.
    Br J Haematol. 2016 Jun 24. doi: 10.1111/bjh.14186.
    PubMed     Text format    


  150. LENNERZ JK, Weissinger SE, Gerstenmaier U, Marienfeld R, et al
    Silencer of Cytokine Signaling 1 gene is not hypermethylated in diffuse large B-cell lymphoma.
    Br J Haematol. 2016 Jun 15. doi: 10.1111/bjh.14188.
    PubMed     Text format    


  151. KRITHARIS A, Pilichowska M, Evens AM
    How I manage patients with grey zone lymphoma.
    Br J Haematol. 2016 Jun 15. doi: 10.1111/bjh.14174.
    PubMed     Text format     Abstract available


  152. JOHNSON A, Morosini D, Vergilio JA, Yelensky R, et al
    Unique genomic features in adolescent and young adult, as compared to older adult, non-Hodgkin lymphoma and potential therapeutic targets.
    Br J Haematol. 2016 Jun 12. doi: 10.1111/bjh.14157.
    PubMed     Text format    


  153. WILLIAMS ME, Hong F, Gascoyne RD, Wagner LI, et al
    Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin lymphomas: Eastern Cooperative Oncology Group Protocol E4402.
    Br J Haematol. 2016;173:867-75.
    PubMed     Text format     Abstract available


    May 2016
  154. OBRADOR-HEVIA A, Serra-Sitjar M, Rodriguez J, Belayachi L, et al
    Efficacy of the GemOx-R regimen leads to the identification of Oxaliplatin as a highly effective drug against Mantle Cell Lymphoma.
    Br J Haematol. 2016 May 25. doi: 10.1111/bjh.14141.
    PubMed     Text format     Abstract available


  155. MARTINEZ C, Diaz-Lopez A, Rodriguez-Calvillo M, Garcia-Sanz R, et al
    Phase II trial of ofatumumab plus ESHAP (O-ESHAP) as salvage treatment for patients with relapsed or refractory classical Hodgkin lymphoma after first-line chemotherapy.
    Br J Haematol. 2016 May 17. doi: 10.1111/bjh.14133.
    PubMed     Text format     Abstract available


  156. GREEN TM, Jensen AK, Holst R, Falgreen S, et al
    Multiplex polymerase chain reaction-based prognostic models in diffuse large B-cell lymphoma patients treated with R-CHOP.
    Br J Haematol. 2016 May 16. doi: 10.1111/bjh.14138.
    PubMed     Text format     Abstract available


  157. CHAGANTI S, Illidge T, Barrington S, Mckay P, et al
    Guidelines for the management of diffuse large B-cell lymphoma.
    Br J Haematol. 2016 May 16. doi: 10.1111/bjh.14136.
    PubMed     Text format    


  158. TUCKER DL, Naylor G, Kruger A, Hamilton MS, et al
    Ibrutinib is a safe and effective therapy for systemic mantle cell lymphoma with central nervous system involvement - a multi-centre case series from the United Kingdom.
    Br J Haematol. 2016 May 16. doi: 10.1111/bjh.14122.
    PubMed     Text format    


  159. TUCKER DL, Mihailescu L, Riordan R, Rule S, et al
    Remineralization of lytic bone disease in a patient with small lymphocytic lymphoma using ibrutinib.
    Br J Haematol. 2016 May 12. doi: 10.1111/bjh.14118.
    PubMed     Text format    


  160. HATTORI K, Sakata-Yanagimoto M, Okoshi Y, Goshima Y, et al
    MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma.
    Br J Haematol. 2016 May 10. doi: 10.1111/bjh.14080.
    PubMed     Text format    


  161. JETHWA KD, Bishton MJ, Fox CP
    The role of high-dose chemotherapy and autologous stem cell transplant for treatment-naIotave patients with peripheral T-cell lymphoma: a systematic review of the literature.
    Br J Haematol. 2016 May 5. doi: 10.1111/bjh.14130.
    PubMed     Text format    


  162. SAWALHA Y, Rouphail B, Jia X, Dean RM, et al
    Is rituximab sub-optimally dosed in indolent B cell lymphoma?
    Br J Haematol. 2016 May 2. doi: 10.1111/bjh.14114.
    PubMed     Text format     Abstract available


  163. NA R, Laaksonen MA, Grulich AE, Meagher NS, et al
    Iatrogenic immunosuppression and risk of non-Hodgkin lymphoma in solid organ transplantation: A population-based cohort study in Australia.
    Br J Haematol. 2016 May 2. doi: 10.1111/bjh.14083.
    PubMed     Text format     Abstract available


  164. GUISADO-VASCO P, Montalban C, Garcia JF
    Comments on the value International Prognostic Score (IPS), stage IV and age over 45 years, for the outcome of advanced Hodgkin lymphoma in chemotherapy containing adriamycin. The experience of the Spanish Hodgkin Lymphoma Study Group.
    Br J Haematol. 2016 May 2. doi: 10.1111/bjh.14127.
    PubMed     Text format    


  165. CAIRO MS, Pinkerton R
    Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science.
    Br J Haematol. 2016 May 2. doi: 10.1111/bjh.14035.
    PubMed     Text format     Abstract available


  166. FEND F, Ferreri AJ, Coupland SE
    How we diagnose and treat vitreoretinal lymphoma.
    Br J Haematol. 2016 May 2. doi: 10.1111/bjh.14025.
    PubMed     Text format     Abstract available


    April 2016
  167. VILLEGAS DA ROS C, Linares Garcia M, Ortiz Zuluaga S, Javier Gonzalez K, et al
    Validation of R-MIPI and prognostic value of immunoglobulin light chain restriction in mantle cell lymphoma.
    Br J Haematol. 2016 Apr 29. doi: 10.1111/bjh.14109.
    PubMed     Text format    


  168. SOUTO FILHO JT, de Souza LB, Baptista LR, de Almeida BI, et al
    Bilateral papilloedema in a patient with non-Hodgkin lymphoma: is there central nervous system infiltration?
    Br J Haematol. 2016 Apr 26. doi: 10.1111/bjh.14111.
    PubMed     Text format    


  169. PETTENGELL R, Sebban C, Zinzani PL, Derigs HG, et al
    Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial.
    Br J Haematol. 2016 Apr 26. doi: 10.1111/bjh.14101.
    PubMed     Text format     Abstract available


  170. GOY A, Forero A, Wagner-Johnston N, Christopher Ehmann W, et al
    A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.
    Br J Haematol. 2016 Apr 22. doi: 10.1111/bjh.14094.
    PubMed     Text format     Abstract available


  171. PINKERTON R, Cairo MS, Cotter FE
    Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science.
    Br J Haematol. 2016 Apr 21. doi: 10.1111/bjh.14091.
    PubMed     Text format    


  172. BRITO AB, Delamain MT, de Oliveira C, Fanelli MF, et al
    Association of BAX G(-248)A and BCL2 C(-717)A polymorphisms with outcome in diffuse large B-cell lymphoma patients.
    Br J Haematol. 2016 Apr 21. doi: 10.1111/bjh.14089.
    PubMed     Text format    


  173. UJJANI CS, Hill EM, Wang H, Nassif S, et al
    F-FDG PET-CT and trephine biopsy assessment of bone marrow involvement in lymphoma.
    Br J Haematol. 2016 Apr 20. doi: 10.1111/bjh.14071.
    PubMed     Text format     Abstract available


  174. GROSS TG, Biondi A
    Paediatric non-Hodgkin lymphoma in low and middle income countries.
    Br J Haematol. 2016 Apr 20. doi: 10.1111/bjh.14030.
    PubMed     Text format     Abstract available


  175. NAKAYAMA S, Yokote T, Hiraoka N, Nishiwaki U, et al
    Expression of multiple cytokines and chemokine receptor 4 in angioimmunoblastic T-cell lymphoma with abundant plasma cell infiltration involving the skin.
    Br J Haematol. 2016 Apr 12. doi: 10.1111/bjh.14092.
    PubMed     Text format    


  176. KUBO K, Miyazaki Y, Murayama T, Shimazaki R, et al
    A randomized, double-blind trial of pegfilgrastim versus filgrastim for the management of neutropenia during CHASE(R) chemotherapy for malignant lymphoma.
    Br J Haematol. 2016 Apr 12. doi: 10.1111/bjh.14088.
    PubMed     Text format     Abstract available


  177. HOCHBERG J, El-Mallawany NK, Abla O
    Adolescent and young adult non-Hodgkin lymphoma.
    Br J Haematol. 2016 Apr 12. doi: 10.1111/bjh.14074.
    PubMed     Text format     Abstract available


  178. KORESAWA R, Yamazaki K, Oka D, Fujiwara H, et al
    Sphingosine-1-phosphate receptor 1 as a prognostic biomarker and therapeutic target for patients with primary testicular diffuse large B-cell lymphoma.
    Br J Haematol. 2016 Apr 8. doi: 10.1111/bjh.14054.
    PubMed     Text format     Abstract available


  179. BARTH MJ, Chu Y, Hanley PJ, Cairo MS, et al
    Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non-Hodgkin lymphoma.
    Br J Haematol. 2016 Apr 7. doi: 10.1111/bjh.14078.
    PubMed     Text format     Abstract available


  180. BARTA SK, Joshi J, Mounier N, Xue X, et al
    Central nervous system involvement in AIDS-related lymphomas.
    Br J Haematol. 2016 Apr 7. doi: 10.1111/bjh.13998.
    PubMed     Text format     Abstract available


  181. HAVELANGE V, Pepermans X, Ameye G, Theate I, et al
    Genetic differences between paediatric and adult Burkitt lymphomas.
    Br J Haematol. 2016;173:137-44.
    PubMed     Text format     Abstract available


    March 2016
  182. WANG SS, Luo J, Cozen W, Lu Y, et al
    Sun sensitivity, indoor tanning and B-cell non-Hodgkin lymphoma risk among Caucasian women in Los Angeles County.
    Br J Haematol. 2016 Mar 31. doi: 10.1111/bjh.14051.
    PubMed     Text format    


  183. TAKAHASHI H, Watanabe T, Kinoshita A, Yuza Y, et al
    High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group.
    Br J Haematol. 2016 Mar 31. doi: 10.1111/bjh.14068.
    PubMed     Text format     Abstract available


  184. SHIELS MS, Pfeiffer RM, Besson C, Clarke CA, et al
    Trends in primary central nervous system lymphoma incidence and survival in the U.S.
    Br J Haematol. 2016 Mar 28. doi: 10.1111/bjh.14073.
    PubMed     Text format     Abstract available


  185. HITZ F, Zucca E, Pabst T, Fischer N, et al
    Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.
    Br J Haematol. 2016 Mar 28. doi: 10.1111/bjh.14049.
    PubMed     Text format     Abstract available


  186. CHO H, Chang JH, Kim YR, Kim SJ, et al
    The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma.
    Br J Haematol. 2016 Mar 28. doi: 10.1111/bjh.14069.
    PubMed     Text format     Abstract available


  187. GALARDY PJ, Bedekovics T, Hermiston ML
    Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons.
    Br J Haematol. 2016 Mar 27. doi: 10.1111/bjh.14016.
    PubMed     Text format     Abstract available


  188. COIFFIER B, Thieblemont C, de Guibert S, Dupuis J, et al
    A phase II, single-arm, multicentre study of coltuximab ravtansine (SAR3419) and rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma.
    Br J Haematol. 2016 Mar 24. doi: 10.1111/bjh.13992.
    PubMed     Text format     Abstract available


  189. SHIRAMIZU B, Mussolin L, Woessmann W, Klapper W, et al
    Paediatric non-Hodgkin lymphoma - perspectives in translational biology.
    Br J Haematol. 2016 Mar 24. doi: 10.1111/bjh.14009.
    PubMed     Text format     Abstract available


  190. SHANKAR AG, Kirkwood AA, Depani S, Bianchi E, et al
    Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents - a report from the United Kingdom's Children's Cancer and Leukaemia Study Group.
    Br J Haematol. 2016 Mar 21. doi: 10.1111/bjh.13979.
    PubMed     Text format     Abstract available


  191. GIULINO-ROTH L, Goldman S
    Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children.
    Br J Haematol. 2016 Mar 21. doi: 10.1111/bjh.13969.
    PubMed     Text format     Abstract available


  192. PILLAI V, Tallarico M, Bishop MR, Lim MS, et al
    Mature T- and NK-cell non-Hodgkin lymphoma in children and young adolescents.
    Br J Haematol. 2016 Mar 15. doi: 10.1111/bjh.14044.
    PubMed     Text format     Abstract available


  193. BURKHARDT B, Mueller S, Khanam T, Perkins SL, et al
    Current status and future directions of T-lymphoblastic lymphoma in children and adolescents.
    Br J Haematol. 2016 Mar 15. doi: 10.1111/bjh.14017.
    PubMed     Text format     Abstract available


  194. DACHY G, Connerotte T
    Vanishing bile duct syndrome associated with diffuse large B-cell lymphoma.
    Br J Haematol. 2016 Mar 14. doi: 10.1111/bjh.14004.
    PubMed     Text format    


  195. MILES RR, Shah RK, Frazer JK
    Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.
    Br J Haematol. 2016 Mar 11. doi: 10.1111/bjh.14011.
    PubMed     Text format     Abstract available


  196. EYRE TA, Linton KM, Rohman P, Kothari J, et al
    Results of a multicentre UK-wide retrospective study evaluating the efficacy of pixantrone in relapsed, refractory diffuse large B cell lymphoma.
    Br J Haematol. 2016 Mar 9. doi: 10.1111/bjh.14021.
    PubMed     Text format     Abstract available


  197. STARR AG, Caimi PF, Fu P, Massoud MR, et al
    Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes.
    Br J Haematol. 2016 Mar 8. doi: 10.1111/bjh.13975.
    PubMed     Text format     Abstract available


  198. PERRY AM, Perner Y, Diebold J, Nathwani BN, et al
    Non-Hodgkin lymphoma in Southern Africa: review of 487 cases from The International Non-Hodgkin Lymphoma Classification Project.
    Br J Haematol. 2016;172:716-23.
    PubMed     Text format     Abstract available


  199. XU L, Hunter ZR, Tsakmaklis N, Cao Y, et al
    Clonal architecture of CXCR4 WHIM-like mutations in Waldenstrom Macroglobulinaemia.
    Br J Haematol. 2016;172:735-44.
    PubMed     Text format     Abstract available


    February 2016
  200. MANSO R, Roncador G, Montes-Moreno S, Rojo F, et al
    p-MAPK1 expression associated with poor prognosis in angioimmunoblastic T-cell lymphoma patients.
    Br J Haematol. 2016 Feb 25. doi: 10.1111/bjh.13972.
    PubMed     Text format    


  201. STANLEY CC, Westmoreland KD, Heimlich BJ, El-Mallawany NK, et al
    Outcomes for paediatric Burkitt lymphoma treated with anthracycline-based therapy in Malawi.
    Br J Haematol. 2016 Feb 23. doi: 10.1111/bjh.13986.
    PubMed     Text format     Abstract available


  202. RAUERT-WUNDERLICH H, Rudelius M, Ott G, Rosenwald A, et al
    Targeting protein kinase C in mantle cell lymphoma.
    Br J Haematol. 2016 Feb 23. doi: 10.1111/bjh.13973.
    PubMed     Text format     Abstract available


  203. SMELAND KB, Kiserud CE, Lauritzsen GF, Blystad AK, et al
    A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma.
    Br J Haematol. 2016 Feb 23. doi: 10.1111/bjh.13965.
    PubMed     Text format     Abstract available


  204. CENCINI E, Fabbri A, Bocchia M
    Rituximab plus ABVD in newly diagnosed nodular lymphocyte-predominant Hodgkin lymphoma.
    Br J Haematol. 2016 Feb 23. doi: 10.1111/bjh.14001.
    PubMed     Text format    


  205. TURNER SD, Lamant L, Kenner L, Brugieres L, et al
    Anaplastic large cell lymphoma in paediatric and young adult patients.
    Br J Haematol. 2016 Feb 23. doi: 10.1111/bjh.13958.
    PubMed     Text format     Abstract available


  206. CHANG JE, Havighurst T, Kim K, Eickhoff J, et al
    Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wisconsin Oncology Network Study.
    Br J Haematol. 2016 Feb 23. doi: 10.1111/bjh.13957.
    PubMed     Text format     Abstract available


  207. VATOPOULOU T, Lawson C, Pocock C
    A case of Stage IA classical Hodgkin lymphoma with FDG-avid tonsils.
    Br J Haematol. 2016 Feb 12. doi: 10.1111/bjh.13953.
    PubMed     Text format    


  208. ILLIDGE TM, McKenzie HS, Mayes S, Bates A, et al
    Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5-year results from a UK National Cancer Research Institute Lymphoma Group study.
    Br J Haematol. 2016 Feb 5. doi: 10.1111/bjh.13954.
    PubMed     Text format     Abstract available


  209. LUNNING MA, Migliacci JC, Hilden P, Devlin SM, et al
    The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of </=12 months.
    Br J Haematol. 2016 Feb 5. doi: 10.1111/bjh.13947.
    PubMed     Text format     Abstract available


  210. MARTIN A, Redondo AM, Dlouhy I, Salar A, et al
    Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 1b study from GELTAMO group.
    Br J Haematol. 2016 Feb 5. doi: 10.1111/bjh.13945.
    PubMed     Text format     Abstract available


  211. JAKOBSEN LH, Hutchings M, de Nully Brown P, Linderoth J, et al
    No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.
    Br J Haematol. 2016 Feb 5. doi: 10.1111/bjh.13943.
    PubMed     Text format     Abstract available


    January 2016
  212. KWONG YL, Lopes D, Khong PL
    Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma.
    Br J Haematol. 2016 Jan 15. doi: 10.1111/bjh.13920.
    PubMed     Text format    


  213. ZALLIO F, Tamiazzo S, Monagheddu C, Merli F, et al
    Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL).
    Br J Haematol. 2016 Jan 13. doi: 10.1111/bjh.13904.
    PubMed     Text format     Abstract available


  214. ARMAND P, Kim HT, Sainvil MM, Lange PB, et al
    The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial.
    Br J Haematol. 2016 Jan 5. doi: 10.1111/bjh.13931.
    PubMed     Text format     Abstract available


  215. NASTOUPIL LJ, Sinha R, Byrtek M, Ziemiecki R, et al
    Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era.
    Br J Haematol. 2016 Jan 5. doi: 10.1111/bjh.13895.
    PubMed     Text format     Abstract available


  216. ARMAND P, Redd R, Bsat J, Mayuram S, et al
    A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.
    Br J Haematol. 2016 Jan 5. doi: 10.1111/bjh.13929.
    PubMed     Text format     Abstract available


  217. CASTELLI R, Wu MA, Arquati M, Zanichelli A, et al
    High prevalence of splenic marginal zone lymphoma among patients with acquired C1 inhibtor deficiency.
    Br J Haematol. 2016 Jan 5. doi: 10.1111/bjh.13908.
    PubMed     Text format     Abstract available


  218. BHULLER KS, Zhang Y, Li D, Sehn LH, et al
    Late mortality, secondary malignancy and hospitalisation in teenage and young adult survivors of Hodgkin lymphoma: report of the Childhood/Adolescent/Young Adult Cancer Survivors Research Program and the BC Cancer Agency Centre for Lymphoid Cancer.
    Br J Haematol. 2016 Jan 5. doi: 10.1111/bjh.13903.
    PubMed     Text format     Abstract available


  219. MOENEN FC, Bakers FC, Bos GM
    Pancreatic atrophy after allogeneic peripheral blood stem cell transplantation.
    Br J Haematol. 2016;172:155.
    PubMed     Text format    


    December 2015
  220. GUPTA A, Chen W, Naina HV
    Lymphadenopathy following cardiac resuscitation in a patient with a previous lymphoma.
    Br J Haematol. 2015 Dec 21. doi: 10.1111/bjh.13894.
    PubMed     Text format    


  221. SCHERER F, van der Burgt M, Kielbasa SM, Bertinetti-Lapatki C, et al
    Selection patterns of B-cell receptors and the natural history of follicular lymphoma.
    Br J Haematol. 2015 Dec 21. doi: 10.1111/bjh.13901.
    PubMed     Text format    


  222. GARCIAZ S, Harel S, Amorim S, Bouabdallah R, et al
    Rituximab-ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy.
    Br J Haematol. 2015 Dec 18. doi: 10.1111/bjh.13879.
    PubMed     Text format    


  223. PERRY AM, Diebold J, Nathwani BN, MacLennan KA, et al
    Relative frequency of non-Hodgkin lymphoma subtypes in selected centres in North Africa, the middle east and India: a review of 971 cases.
    Br J Haematol. 2015 Dec 18. doi: 10.1111/bjh.13876.
    PubMed     Text format     Abstract available


  224. SHIBA N, Ohki K, Kobayashi T, Hara Y, et al
    High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.
    Br J Haematol. 2015 Dec 18. doi: 10.1111/bjh.13869.
    PubMed     Text format     Abstract available


  225. MACIOCIA P, Badat M, Cheesman S, D'Sa S, et al
    Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy.
    Br J Haematol. 2015 Dec 18. doi: 10.1111/bjh.13867.
    PubMed     Text format     Abstract available


  226. CHEAH CY, Nastoupil LJ, McLaughlin P, Fanale MA, et al
    Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
    Br J Haematol. 2015 Dec 18. doi: 10.1111/bjh.13863.
    PubMed     Text format    


  227. CHIHARA D, Cheah CY, Westin JR, Fayad LE, et al
    Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.
    Br J Haematol. 2015 Dec 9. doi: 10.1111/bjh.13796.
    PubMed     Text format     Abstract available


  228. ADVANI RH, Ansell SM, Lechowicz MJ, Beaven AW, et al
    A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
    Br J Haematol. 2015 Dec 2. doi: 10.1111/bjh.13855.
    PubMed     Text format     Abstract available


    November 2015
  229. BISHTON MJ, Hughes S, Richardson F, James E, et al
    Delineating Outcomes of Patients with Diffuse Large B cell lymphoma using the National Comprehensive Cancer Network-International Prognostic Index and Positron Emission Tomography-defined Remission Status; a Population-based Analysis.
    Br J Haematol. 2015 Nov 18. doi: 10.1111/bjh.13831.
    PubMed     Text format     Abstract available


  230. GIBSON SE, Leeman-Neill RJ, Jain S, Piao W, et al
    Proliferation centres of chronic lymphocytic leukaemia/small lymphocytic lymphoma have enhanced expression of MYC protein, which does not result from rearrangement or gain of the MYC gene.
    Br J Haematol. 2015 Nov 16. doi: 10.1111/bjh.13844.
    PubMed     Text format    


  231. FORERO-CASTRO M, Robledo C, Lumbreras E, Benito R, et al
    The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.
    Br J Haematol. 2015 Nov 16. doi: 10.1111/bjh.13849.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: